Deferasirox (Exjade®, ICL670) treatment of inadequately chelated β-thalassemia patients from the Middle East:: The ESCALATOR trial.

被引：0
|
作者：
Taher, A
El-Beshlawy, A
Al Jefri, A
El Alfy, M
Al Zir, K
Daar, S
Al-Damanhouri, G
Hadler, D
Krahn, U
机构：
[1] Amer Univ Beirut, Chron Care Ctr, Beirut, Lebanon
[2] Cairo Univ, Cairo, Egypt
[3] King Faisal Specialist Hosp & Res Ctr, Riyadh 11211, Saudi Arabia
[4] Ain Shams Univ, Cairo, Egypt
[5] Natl Thalassemia Ctr, Damascus, Syria
[6] Sultan Qaboos Univ, Muscat, Oman
[7] King Abdulaziz Univ Hosp, Jeddah, Saudi Arabia
[8] Novartis Pharma AG, Basel, Switzerland
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3840
引用
收藏
页码：40B / 41B
页数：2
相关论文
共 50 条
  • [31] Phase III evaluation of once-daily, oral therapy with ICL670 (Exjade®) versus deferoxamine in patients with β-thalassemia and transfusional hemosiderosis
    Cappellini, M
    Bejaoui, M
    Perrotta, S
    Agaoglu, L
    Kattamis, A
    Giardina, P
    Janka-Schaub, G
    Opitz, H
    Ressayre-Djaffer, C
    Alberti, D
    BLOOD, 2004, 104 (11) : 984A - 984A
  • [32] The once-daily oral iron chelator deferasirox (Exjade®, ICL670) is effective and generally well tolerated during long-term treatment in pediatric patients
    Vichinsky, E.
    Paley, C.
    PEDIATRIC BLOOD & CANCER, 2007, 48 (06) : 608 - 609
  • [33] Control of oxidant-stress and inflammation by iron chelators deferasirox (ICL670) or deferoxamine in β-thalassemia:: An ancillary study of the novartis CICL670A0107 trial
    Walter, P
    Macklin, E
    Porter, J
    Evans, P
    Coates, T
    Olivieri, NF
    Giardina, P
    Kwiatkowski, J
    Neufeld, E
    Ames, B
    Holland, J
    Marks, P
    Vichinsky, E
    Harmatz, P
    BLOOD, 2005, 106 (11) : 1003A - 1003A
  • [34] Liver iron concentration measurements using MRI R2 in MDS patients in a deferasirox (Exjade®, ICL670) phase II study.
    Greenberg, Peter L.
    Schiffer, Charles A.
    Koller, Charles Asa
    Kang, Barinder
    Decker, Jodie
    Paley, Carole
    BLOOD, 2006, 108 (11) : 297B - 297B
  • [35] Long-term efficacy and safety of deferasirox (Exjade®, ICL670), a once-daily oral iron chelator, in patients with sickle cell disease (SCD)
    Vichinsky, Elliott
    Coates, Thomas D.
    Thompson, Alexis A.
    Mueller, Brigitta U.
    Lagrone, Darlene
    Heeney, Matthew M.
    BLOOD, 2007, 110 (11) : 995A - 995A
  • [36] Impact of dose adjustments on serum ferritin (SF) levels during long-term treatment with once-daily, oral deferasirox (Exjade®, ICL670)
    Porter, John B.
    Cohen, Alan R.
    Ford, John M.
    Cappellini, Maria Domenica
    BLOOD, 2007, 110 (11) : 816A - 817A
  • [37] Long-term safety and tolerability of the once-daily, oral iron chelator deferasirox (Exjade®, ICL670) in patients with transfusional iron overload.
    Cappellini, M. D.
    Giardina, P.
    Porter, J.
    Coates, T.
    Della Porta, M. G.
    Siegel, J.
    Glimm, E.
    Ford, J.
    Cappellini, Maria Dominica
    BLOOD, 2006, 108 (11) : 501A - 501A
  • [38] A safety, pharmacokinetic and pharmacodynamic investigation of deferasirox (Exjade®, ICL670) in patients with transfusion-dependent anemias and iron-overload:: a Phase I study in Japan
    Miyazawa, Keisuke
    Ohyashiki, Kazuma
    Urabe, Akio
    Hata, Tomoko
    Nakao, Shinji
    Ozawa, Keiya
    Ishikawa, Takayuki
    Kato, Junji
    Tatsumi, Yoichi
    Mori, Hiraku
    Kondo, Midori
    Taniguchi, Junsuke
    Tanii, Hiromi
    Rojkjaer, Lisa
    Omine, Mitsuhiro
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2008, 88 (01) : 73 - 81
  • [39] A safety, pharmacokinetic and pharmacodynamic investigation of deferasirox (Exjade®, ICL670) in patients with transfusion-dependent anemias and iron-overload: a Phase I study in Japan
    Keisuke Miyazawa
    Kazuma Ohyashiki
    Akio Urabe
    Tomoko Hata
    Shinji Nakao
    Keiya Ozawa
    Takayuki Ishikawa
    Junji Kato
    Yoichi Tatsumi
    Hiraku Mori
    Midori Kondo
    Junsuke Taniguchi
    Hiromi Tanii
    Lisa Rojkjaer
    Mitsuhiro Omine
    International Journal of Hematology, 2008, 88 : 73 - 81
  • [40] Iron chelation therapy with deferasirox (Exjade®, ICL670) or deferoxamine results in reduced hepatocellular inflammation and improved liver function in patients with transfusion-dependent anemia.
    Brissot, P
    Turlin, B
    Forni, GL
    Alimena, G
    Quarta, G
    Selleslag, D
    Thompson, A
    Locatelli, F
    Berretta, A
    de Montalembert, M
    Ressayre-Djaffer, C
    Rabault, B
    Ford, J
    Alberti, D
    BLOOD, 2005, 106 (11) : 242A - 243A
12345